Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis?
NCT02373020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2015-04-09
Summary
Despite the characterization of many aetiologic genetic changes. The specific causative factors in the development of sporadic colorectal cancer remain unclear. This study was performed to detect the possible role of Enteropathogenic Escherichia coli (EPEC) in developing colorectal carcinoma.
Conditions
- Enteropathogenic Escherichia Coli .
- Colorectal Carcinoma
Interventions
- OTHER
-
colonoscopic biopsies
Sponsors & Collaborators
-
Mansoura University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-01-31
- Primary Completion
- 2013-03-31
- Completion
- 2013-03-31
Countries
- Egypt
Study Locations
More Related Trials
-
Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver
NCT00035919 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
NCT03833700 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers
NCT04103567 ·Status: RECRUITING ·Phase: NA
-
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
NCT01300858 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
NCT00931840 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
NCT06576986 ·Status: RECRUITING ·Phase: NA
-
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
NCT00309179 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study Of The ERCC-1 Gene
NCT00846482 ·Status: COMPLETED ·Phase: NA
-
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
NCT00111761 ·Status: COMPLETED ·Phase: PHASE2
-
Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials
NCT03350412 ·Status: UNKNOWN
-
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
NCT00079066 ·Status: COMPLETED ·Phase: PHASE3
-
PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment
NCT02618850 ·Status: UNKNOWN ·Phase: NA
-
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adjuvant Aflibercept for Metastatic Colorectal Cancer
NCT01669720 ·Status: TERMINATED ·Phase: PHASE2
-
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
NCT00773097 ·Status: COMPLETED ·Phase: PHASE2
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800 ·Status: RECRUITING ·Phase: PHASE3
-
The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer
NCT05579353 ·Status: RECRUITING
-
EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases
NCT00848510 ·Status: COMPLETED ·Phase: PHASE1
-
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients
NCT04753203 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer
NCT01243372 ·Status: COMPLETED
-
The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment
NCT05655780 ·Status: RECRUITING
-
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment
NCT01983098 ·Status: UNKNOWN
-
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT06011772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer
NCT02090101 ·Status: COMPLETED ·Phase: PHASE2